EUCTR2007-004895-37-GB进行中（未招募）1 期
A Phase III, Randomised, Double-Blind, Dose-Response, Stratified, Placebo-Controlled Study Evaluating the Safety and Efficacy of SPD476 versus Placebo over 104 weeks in the Prevention of Recurrence of Diverticulitis
Shire Pharmaceutical Development Limited0 个研究点目标入组 584 人开始时间: 2008年1月7日最近更新:
适应症
相关药物
试验速览
- 阶段
- 1 期
- 状态
- 进行中（未招募）
- 发起方
- 入组人数
- 584
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional clinical trial of medicinal product
入排标准
入选标准
- •1. Written, signed, and dated informed consent to participate in the study must be given by the subject, in accordance with the International Conference on Harmonisation (ICH) Good Clinical Practice (GCP) Guideline E6 and applicable regulations, before completing any study-related procedures listed in Section 6.1.
- •2. Male and female subjects =18 years of age.
- •3. If female of childbearing potential (FOCP), has demonstrated a negative beta HCG (human chorionic gonadotropin) serum pregnancy test, and agrees to comply with any applicable contraceptive requirements of the protocol (refer to Section 4.4).
- •4. At least one documented attack of acute diverticulitis in the previous 24 months that has clinically resolved without colonic resection. Documentation must include a verifiable report confirming acute diverticulitis (examples include CT scan, magnetic resonance imaging (MRI) scan, ultrasound, endoscopy of the sigmoid colon, or barium enema).
- •5. Confirmation of diverticulosis via endoscopic evaluation of the sigmoid colon, with at least three diverticula noted. The presence of mild erythema and loss of vascularity (oedema) is acceptable, whereas frank ulceration and evidence of ischaemia is not.
- •6. White Blood Cell (WBC) count within central laboratory normal reference ranges.
- •7. Polymorphonuclear leukocyte (PMN) level within central laboratory normal reference ranges.
- •8. Subject and investigator must agree that participation in this study is in the best interest of the subject.
- •Are the trial subjects under 18? no
- •Number of subjects for this age range:
- •F.1.2 Adults (18-64 years) yes
- •F.1.2.1 Number of subjects for this age range
- •F.1.3 Elderly (>=65 years) yes
- •F.1.3.1 Number of subjects for this age range
排除标准
- •1. Subjects who have had an attack of diverticulitis and/or continue to exhibit signs and symptoms of diverticulitis within 6 weeks prior to and up to Baseline
- •2. Previous colorectal surgery, including surgical intervention for diverticular disease (with the exception of haemorrhoidectomy, colonic removal of polyps, and appendectomy)
- •3. Clinically relevant gross extraluminal pathology as shown by CT scan
- •4. Right sided diverticulosis only
- •5. Active peptic ulcer disease
- •6. History of or current presence of inflammatory bowel disease (IBD)
- •7. Subjects with active irritable bowel syndrome (IBS) requiring ongoing medication.
- •8. Active GI bleeding, except for positive faecal occult blood test (FOBT) in the stool
- •9. Active or recent history of endometriosis or dysmenorrhoea within 6 months prior to Baseline
- •10. Allergy or hypersensitivity to mesalazine (5-ASA) or aspirin
- •11. Subjects who are unwilling or unable to undergo a CT scan or have a known or suspected allergy to all radiologic contrast agents.
- •12. Subjects must not have used another investigational product within 30 days prior to Baseline
- •13. Within 14 days of Baseline, use of prebiotic, probiotic or 5-ASA medications, as well as drugs active at the 5HT-receptor (e.g., tegaserod, alosetron, metaclopramide) or anti-spasmodic agents
- •14. Any current or historical use of biologics (anti-TNF agents)
- •15. Use of immunomodulators (e.g., azathioprine, 6-mercaptopurine) within 6 weeks prior to Baseline
- •16. Use of systemic or rectal steroids within 6 weeks of Baseline. Use of inhaled or nasal steroids is acceptable
- •17. Subjects who have conditions requiring regular and ongoing use of anti-inflammatory drugs, including non-steroidal anti-inflammatory drugs (NSAIDs), such as aspirin, COX 2 inhibitors, or ibuprofen. Use of aspirin (=325mg/day) taken for cardiac prophylaxis is acceptable
- •18. Subjects with clinically relevant moderate or severe renal or hepatic impairment are contraindicated with mesalazine products
- •19. Current or relevant previous disease that could affect the colon, action, absorption, or disposition of the investigational product, or clinical or laboratory assessments.
- •20. Any history of malignancy, except for basal cell skin cancer, cervical carcinoma in-situ, or carcinoma in-situ in a colonoscopically removed polyp
- •21. Subjects with a history of alcohol or other substance abuse within the previous year
- •22. Females who are lactating
- •23. Current or relevant history of serious, severe, or unstable (acute or progressive) physical or psychiatric illness, any medical disorder that may require treatment or make the subject unlikely to fully complete the study, or any condition that presents undue risk from the study medication or procedures
- •24. Subjects who have previously been screened for or enrolled into this study and subsequently withdrawn
研究者
相似试验
进行中（未招募）
1 期
A study evaluating the efficacy and safety of Etrasimod in the treatment of patients with moderately to severely active Ulcerative Colitislcerative ColitisMedDRA version: 20.1Level: LLTClassification code 10045365Term: Ulcerative colitisSystem Organ Class: 100000004856MedDRA version: 20.1Level: LLTClassification code 10045366Term: Ulcerative colitis, unspecifiedSystem Organ Class: 100000004856EUCTR2018-003985-15-PTArena Pharmaceuticals Inc.433
进行中（未招募）
1 期
Efficacy and safety of Cabozantinib (XL184) in subjects who have progressed after VEGFR-targeted treatmentRadioiodine-Refractory Differentiated Thyroid Cancer which has progressed after priorVEGFR-targeted therapyMedDRA version: 20.0Level: PTClassification code 10066474Term: Thyroid cancerSystem Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)EUCTR2018-001771-21-CZExelixis, Inc.300
进行中（未招募）
1 期
A Phase 3, Randomized, Double-Blind, Placebo-Controlled, Multicenter Study of Niraparib Maintenance Treatment in Patients with Advanced Ovarian Cancer Following Response on Front-Line Platinum-Based ChemotherapyHomologous recombination deficiency advanced ovarian cancerMedDRA version: 20.0Level: PTClassification code 10033128Term: Ovarian cancerSystem Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)EUCTR2015-000952-11-ITTESARO, INCORPORATED733
进行中（未招募）
不适用
A Phase 3, Randomized, Double-Blind, Placebo-Controlled Trial of 48 Weeks of GS-9190 in Combination with Peginterferon Alfa 2a (Pegasys®) and Ribavirin (Copegus®) in Previously Untreated Subjects with Genotype-1 Chronic Hepatitis C Virus (HCV) InfectioEUCTR2009-013442-86-BEGilead Sciences Inc560
招募中
1 期
Placebo-controlled Study Comparing Niraparib Plus Pembrolizumab Versus Placebo Plus Pembrolizumab as Maintenance Therapy in Participants with Advanced/Metastatic Non-Small Cell Lung Cancerung Cancer, Non-Small CellMedDRA version: 21.1Level: PTClassification code: 10029521Term: Non-small cell lung cancer stage IIIB Class: 100000004864MedDRA version: 21.1Level: PTClassification code: 10029522Term: Non-small cell lung cancer stage IV Class: 100000004864MedDRA version: 21.1Level: PTClassification code: 10061873Term: Non-small cell lung cancer Class: 100000004864CTIS2023-508443-40-00Glaxosmithkline Research & Development Limited644